Technical Analysis for ATNX - Athenex, Inc.

Grade Last Price % Change Price Change
grade F 13.22 -1.12% -0.15
ATNX closed down 1.12 percent on Monday, October 15, 2018, on 61 percent of normal volume. The bears made the stock sink to a new 52-week low. The price action carved out a bearish shooting star candlestick pattern. That may indicate a downside reversal. Look for price to trade beneath the low of the shooting star for confirmation. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
0 Watchers
View Intraday Alerts Watchlist Portfolio

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Down
See historical ATNX trend table...

Date Alert Name Type % Chg
Oct 15 New 52 Week Closing Low Bearish 0.00%
Oct 15 Shooting Star Candlestick Bearish 0.00%
Oct 15 Slingshot Bearish Bearish Swing Setup 0.00%
Oct 15 Wide Range Bar Range Expansion 0.00%
Oct 15 Doji - Bearish? Reversal 0.00%
Oct 15 Doji - Bullish? Reversal 0.00%
Oct 15 New 52 Week Low Weakness 0.00%
Oct 15 Outside Day Range Expansion 0.00%
Oct 15 Wide Bands Range Expansion 0.00%
Oct 15 Down 3 Days in a Row Weakness 0.00%

Older signals for ATNX ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Analyze My Stocks!
Configure default chart indicators
Basic chart:

Profile
Athenex, Inc. is an oncology pharmaceutical company focused on the development and commercialization of therapies for cancer diseases and supportive therapies. The Company's technology platform is organized into three categories, including Oral Absorption Platform, Src Kinase Inhibitors and Symptom Therapeutics. The Company offers Oraxol, an oral formulation of paclitaxel; Orateacan, an oral formulation of Irinotecan; Oradoxel, an oral formulation of Docetaxel, and an oral formulation of Topotecan for the treatment of various types of cancers. Its Src Kinase Inhibitors include KX-01 (KX2-391) and KX-02 (KX2-361) oncology drug candidates. The Company's Symptom Therapeutics include CQ-01, which is used for the treatment of burn pruritus and scars; CQ-R1, which is used for the treatment of an irradiation-induced dermatitis, and an intranasal Granisetron used for the treatment of chemotherapy-induced nausea/vomiting.
Is ATNX a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Recent News
Date Title
Oct 15 Athenex reports positive data on T-cell therapy
Oct 15 Athenex and Xiangxue Life Sciences Announce Preliminary Results of Patients Receiving T-Cell Receptor Affinity Enhancing Specific T-Cell Therapy (TAEST) Showed Encouraging Positive Clinical Signals
Sep 25 Report: Developing Opportunities within RLJ Lodging Trust, Solar Capital, Athenex, Bonanza Creek Energy, Mueller Industries, and Corporate Office Properties Trust — Future Expectations, Projections Moving into 2018
Sep 24 Athenex files for mixed shelf offering
Sep 12 Athenex and Hanmi Pharmaceutical announces strategic realignment of their joint projects
Sep 12 Athenex and its Collaborative Partner, Hanmi Pharmaceutical, Announce Strategic Realignment of their Joint Projects
Sep 7 FDA revising collaboration with states to ensure access and quality of compounded drugs
Sep 5 Athenex announces positive recommendation by the DSMB and continues the Oraxol Phase III program
Sep 5 Athenex Announces Positive Recommendation by the Drug Safety Monitoring Board Upon the Second Interim Analysis and to Continue the Oraxol Phase III Program
Aug 27 Endo up 5% on FDA plan to restrict compounding of vasopressin
See more ATNX news...
Indicators
Indicator Value
52 Week High 20.9
52 Week Low 13.15
Average Volume 247,703
200-Day Moving Average 16.7292
50-Day Moving Average 16.2306
20-Day Moving Average 15.1905
10-Day Moving Average 14.26
Average True Range 0.6366
ADX 30.8
+DI 18.8969
-DI 27.239
Chandelier Exit (Long, 3 ATRs ) 15.1702
Chandelier Exit (Short, 3 ATRs ) 15.0598
Upper Bollinger Band 17.4918
Lower Bollinger Band 12.8892
Percent B (%b) 0.07
BandWidth 30.2992
MACD Line -0.8423
MACD Signal Line -0.6498
MACD Histogram -0.1925
Fundamentals Value
Market Cap 754.38 Million
Num Shares 57.1 Million
EPS -3.47
Price-to-Earnings (P/E) Ratio -3.81
Price-to-Sales 47.88
Price-to-Book 7.97
PEG Ratio 0.98
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 15.85
Resistance 3 (R3) 16.11 15.51 15.41
Resistance 2 (R2) 15.51 14.84 15.37 15.26
Resistance 1 (R1) 14.36 14.43 14.06 14.10 15.12
Pivot Point 13.76 13.76 13.61 13.62 13.76
Support 1 (S1) 12.61 13.09 12.31 12.35 11.32
Support 2 (S2) 12.01 12.68 11.87 11.18
Support 3 (S3) 10.86 12.01 11.03
Support 4 (S4) 10.60